SCHEMBL5257989

SCHEMBL5257989

NC[C@H]1COCCO1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL455134 1.00
SCHEMBL8072720 1.00
SCHEMBL7749229 0.97 CHRM2 (0.48)
Hydrochloric Acid SCHEMBL20767612 0.97
Hydrochloric Acid SCHEMBL20797704 0.97
SCHEMBL25124368 0.97 CHRM2 (0.48)
Hydrochloric Acid SCHEMBL20767606 0.97
SCHEMBL1246378 0.97 CHRM2 (0.48)
SCHEMBL6602399 0.97 CHRM2 (0.48)
SCHEMBL18101264 0.97 CHRM2 (0.48)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12583853-B2 1H-pyrrolo[2,3-b]pyridine derivatives and related compounds as BCL-2 inhibitors for the treatment of neoplastic and autoimmune diseases NEWAVE PHARMACEUTICAL INC. (US) 2026-03-24 US disclosed
US-12552784-B2 1H-pyrrolo[2,3-b]pyridine derivatives as BCL-2 inhibitors for the treatment of neoplastic and autoimmune diseases NEWAVE PHARMACEUTICAL INC. (US) 2026-02-17 US disclosed
CN-116217566-B Anti-apoptosis protein BCL-2 inhibitor, pharmaceutical composition and application thereof 杭州和正医药有限公司 2025-05-23 CN disclosed
US-20250114374-A1 BCL-2 INHIBITORS NEWAVE PHARMACEUTICAL INC. 2025-04-10 US disclosed
US-12220419-B2 BCL-2 inhibitors NEWAVE PHARMACEUTICAL INC. (US) 2025-02-11 US disclosed
CN-115490708-B Sulfonamide macrocyclic derivative, preparation method and application thereof 苏州亚盛药业有限公司 2025-01-24 CN disclosed
EP-4442685-A1 ANTI-APOPTOTIC PROTEIN BCL-2 INHIBITOR, PHARMACEUTICAL COMPOSITION AND USES THEREOF Hangzhou HealZen Therapeutics Co., Ltd. (CN) 2024-10-09 EP disclosed
WO-2024127350-A1 2,6,9-TRISUBSTITUTED PURINES ASTRAZENECA AB (SE) 2024-06-20 WO disclosed
US-20240180924-A1 BCL-2 INHIBITORS NEWAVE PHARMACEUTICAL INC. 2024-06-06 US disclosed
US-20240166646-A1 1H-PYRROLO[2,3-B]PYRIDINE DERIVATIVES AS BCL-2 INHIBITORS FOR THE TREATMENT OF NEOPLASTIC AND AUTOIMMUNE DISEASES NEWAVE PHARMACEUTICAL INC. 2024-05-23 US disclosed
US-20140057927-A1 INHIBITORS OF BETA-SECRETASE VITAE PHARMACEUTICALS, INC. 2014-02-27 US disclosed
US-20140057927-A1 INHIBITORS OF BETA-SECRETASE VITAE PHARMACEUTICALS, INC. 2014-02-27 US disclosed
US-20130289050-A1 INHIBITORS OF BETA-SECRETASE VITAE PHARMACEUTICALS, INC. (US) 2013-10-31 US disclosed
WO-2013134085-A1 INHIBITORS OF BETA-SECRETASE BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-09-12 WO disclosed
US-7279487-B2 Hydroxynaphthyridinone carboxamides useful as HIV integrase inhibitors MERCK & CO., INC. (US) 2007-10-09 US disclosed
EP-1467970-B1 HYDROXYNAPHTHYRIDINONE CARBOXAMIDES USEFUL AS HIV INTEGRASE INHIBITORS MERCK & CO INC (US) 2007-08-22 EP disclosed
EP-1467970-A4 HYDROXYNAPHTHYRIDINONE CARBOXAMIDES USEFUL AS HIV INTEGRASE INHIBITORS MERCK & CO INC (US) 2005-12-21 EP disclosed
US-20050119482-A1 Hydroxynaphthyridinone carboxamides useful as hiv integrase inhibitors MERCK SHARP & DOHME CORP. 2005-06-02 US disclosed
EP-1467970-A1 HYDROXYNAPHTHYRIDINONE CARBOXAMIDES USEFUL AS HIV INTEGRASE INHIBITORS Merck & Co., Inc. (US) 2004-10-20 EP disclosed
WO-2003062204-A1 HYDROXYNAPHTHYRIDINONE CARBOXAMIDES USEFUL AS HIV INTEGRASE INHIBITORS MERCK & CO., INC. (US) 2003-07-31 WO disclosed